IAIsabelle Alves de Almeida

Isabelle Alves de Almeida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabelle Alves de Almeida has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the Completeness of Visceral Leishmaniasis Records in the Health Region – Açailandia (Region XIV), Maranhão, Brazil

    by João Guilherme Nantes Araújo, Vitória Rauane Simplicio Sobrinho, Larissa Barbosa Cerquinho, Isabelle Alves de Almeida, Joicy Cortez de Sá Sousa, Amanda Silva dos Santos Aliança

    Objective: Analyze the completeness of the mandatory and essential fields that must appear in Sinan regarding visceral leishmaniasis, in the years 2019 to 2022 of the Health Region – Açailândia (Region XIV), Maranhão, Brazil. Theoretical Framework: In Brazil, it is compulsory to report, requiring complete data for effective monitoring. Maranhão, especially Açailândia, faces a high incidence due to deforestation and precarious conditions, making it urgent to implement integrated public health control and prevention strategies. Method: Quantitative descriptive study based on data analysis from DataSUS, where essential fields and mandatory fields were considered to evaluate the completeness of the forms. Results and Discussion: During the study period, 48 notifications were computed and evaluated, in the essential fields, the “residence area” was the one with the lowest completeness categorized as “Poor” with 0%, the other variables presented good completeness, with more than 95% and the “Race/color” variable is the only one with 100%. Of the mandatory variables, “Coinfection with HIV” and “Type of entry” were the only ones that achieved lower completeness (87.5% and 93.75%, respectively) and the variables “sex”, “age group” and “diagnosis confirmation criteria” reaching 100% completeness. Research Implications: Research has important implications for improving Epidemiological Surveillance, Formulating Public Policies and Training Health Professionals, making screening and combating visceral leishmaniasis more efficient.

  • Open Access

    Bioprospecting of secondary metabolites produced by endophytic actinomycete isolated from Aloe vera

    by Fernanda Costa Rosa, Isabelle Alves de Almeida, Alexya Gonçalves Mota, Rita de Cássia Mendonça de Miranda

    The aim of this work to evaluate the antibacterial action of secondary metabolites produced by endophytic actinomycetes, against isolates of medical interest. For such, the bacteria were isolated from the botanical sample and classical morphological identification was performed. The induction of metabolites production was carried out using the Submerged Fermentation technique, followed by purification of the extract. The evaluation of antibacterial activity was accomplished by using agar diffusion and Minimum Inhibitory Concentration (MIC) assays. Macro and microscopic analysis of the grown microorganism allowed it to be identified as belonging to the genus Streptomyces. Test results demonstrated that the extract was able to inhibit the growth of C. propinquum 431024, with an inhibition zone of 27±0 mm and of C. propinquum 36063, with an inhibition zone of 24±0 mm and MIC of 32.1 µg/mL for boths. The evaluation of biofilm formation resulted in: C. propinquun 421024 as a weak producer and C. propinquun 36063 as a moderate producer. The biofilm interference test showed that compared to the control there was a reduction in biofilm formation of 22% for C. propinquun 421024, as well as a reduction in pre-formed biofilm of 27%. There was a 48% reduction in the formation and 42% in the pre-formed biofilm of C. propinquun 36063. Lastly, it was concluded that the secondary metabolites produced by the endophytic actinomycetes demonstrated an antibiotic potential against clinical strains (nasopharynx) of Corynebacterium propinquum, a rare pathogen described for causing infections in patients with pulmonary involvement, pleural effusion, bacteremia and endocarditis and which presents an emerging antibiotic resistance.